HomeCompareCNBI vs VICI

CNBI vs VICI: Dividend Comparison 2026

CNBI yields 1000000.00% · VICI yields 6.52%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CNBI wins by $4.7683925249533696e+36M in total portfolio value
10 years
CNBI
CNBI
● Live price
1000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.7683925249533696e+36M
Annual income
$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00
Full CNBI calculator →
VICI
VICI Properties Inc.
● Live price
6.52%
Share price
$27.32
Annual div
$1.78
5Y div CAGR
44.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$966.2K
Annual income
$607,376.13
Full VICI calculator →

Portfolio growth — CNBI vs VICI

📍 CNBI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCNBIVICI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CNBI + VICI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CNBI pays
VICI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CNBI
Annual income on $10K today (after 15% tax)
$85,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/yr
VICI
Annual income on $10K today (after 15% tax)
$554.58/yr
After 10yr DRIP, annual income (after tax)
$516,269.71/yr
At 15% tax rate, CNBI beats the other by $4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CNBI + VICI for your $10,000?

CNBI: 50%VICI: 50%
100% VICI50/50100% CNBI
Portfolio after 10yr
$2.3841962624766848e+36M
Annual income
$2,383,727,347,228,033,600,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on VICI right now

CNBI
No analyst data
Altman Z
2.3
Piotroski
4/9
VICI
Analyst Ratings
20
Buy
6
Hold
Consensus: Buy
Price Target
$31.60
+15.7% upside vs current
Range: $30.00 — $33.00
Altman Z
1.4
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CNBI buys
0
VICI buys
11
PoliticianChamberTickerTypeAmountDate
Ro Khanna🏢 House$VICI▲ Buy$1,001 - $15,0002024-10-14
Ro Khanna🏢 House$VICI▲ Buy$1,001 - $15,0002024-03-25
Ro Khanna🏢 House$VICI▼ Sell$1,001 - $15,0002024-03-20
Ro Khanna🏢 House$VICI▼ Sell$1,001 - $15,0002024-02-13
Ro Khanna🏢 House$VICI▼ Sell$1,001 - $15,0002023-11-03
Ro Khanna🏢 House$VICI▲ Buy$1,001 - $15,0002023-10-10
Ro Khanna🏢 House$VICI▼ Sell$1,001 - $15,0002023-09-06
Ro Khanna🏢 House$VICI▲ Buy$1,001 - $15,0002023-08-29
Ro Khanna🏢 House$VICI▲ Buy$1,001 - $15,0002023-07-28
Ro Khanna🏢 House$VICI▲ Buy$1,001 - $15,0002023-06-29
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCNBIVICI
Forward yield1000000.00%6.52%
Annual dividend / share$2.00$1.78
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%44.3%
Portfolio after 10y$4.7683925249533696e+36M$966.2K
Annual income after 10y$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$607,376.13
Total dividends collected$4.7683311610149396e+36M$926.2K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: CNBI vs VICI ($10,000, DRIP)

YearCNBI PortfolioCNBI Income/yrVICI PortfolioVICI Income/yrGap
1← crossover$100,010,700$100,000,000.00$11,361$941.49+$100.00MCNBI
2$934,786,450,701$934,679,439,252.34$13,320$1,481.32+$934786.44MCNBI
3$8,165,787,108,578,292$8,164,786,887,076,042.00$16,284$2,405.01+$8165787108.56MCNBI
4$66,665,884,190,957,650,000$66,657,146,798,751,470,000.00$21,040$4,071.78+$66665884190957.63MCNBI
5$508,662,171,058,048,100,000,000$508,590,838,561,963,700,000,000.00$29,209$7,285.49+$508662171058048128.00MCNBI
6$3,627,235,248,428,489,700,000,000,000$3,626,690,979,905,457,600,000,000,000.00$44,443$14,006.51+$3.62723524842849e+21MCNBI
7$24,173,681,159,150,610,000,000,000,000,000$24,169,800,017,434,790,000,000,000,000,000.00$75,822$29,512.55+$2.417368115915061e+25MCNBI
8$150,567,402,861,454,640,000,000,000,000,000,000$150,541,537,022,614,370,000,000,000,000,000,000.00$148,733$69,726.75+$1.5056740286145463e+29MCNBI
9$876,477,100,281,847,600,000,000,000,000,000,000,000$876,315,993,160,785,800,000,000,000,000,000,000,000.00$344,394$189,413.75+$8.764771002818475e+32MCNBI
10$4,768,392,524,953,369,600,000,000,000,000,000,000,000,000$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$966,234$607,376.13+$4.7683925249533696e+36MCNBI

CNBI vs VICI: Complete Analysis 2026

CNBIStock

China BCT Pharmacy Group, Inc., through its subsidiaries, operates as an integrated pharmaceutical company in the People's Republic of China. It operates through three segments: Pharmaceutical Distribution, Retail Pharmacy, and Manufacturing Pharmacy. The Pharmaceutical Distribution segment purchases pharmaceutical products from suppliers and distributes them to hospitals, retail drug stores, other pharmaceutical wholesalers, clinics, medical centers, and individuals. It offers approximately 8,000 pharmaceutical and healthcare products, including branded and generic prescription medicines, over-the counter medicines, and Western and Chinese medicines, as well as personal care products and medical supplies, Chinese herbs, and medical instruments. The Retail Pharmacy segment operates a retail pharmacy network of 196 directly owned stores, primarily in Guangxi province under the Baicaotang name. The retail stores provide professional pharmaceutical services, and supply various medicines, such as prescription medicines, over-the-counter medicines, Chinese herbal medicine, roughly processed Chinese herbal medicine, family planning products, and other pharmaceutical and healthcare products. The Manufacturing Pharmacy segment manufactures and sells generic and clinic drugs, such as traditional anti-inflammatory and antibacterial drugs, cancer treatment drugs, cardio-vascular disease drugs, and hepatitis drugs under the Asio name. Its products comprise Levodopa, Tabellae Sarcandrae, Rotandine Sulfate, Corydalis Saxicola Bunting, and Ethacridine Lactate injection. The company was formerly known as China Baicaotang Medicine Limited and changed its name to China BCT Pharmacy Group, Inc. in March 2010. China BCT Pharmacy Group, Inc. is headquartered in Liuzhou, the People's Republic of China.

Full CNBI Calculator →

VICIREIT

VICI Properties is an experiential real estate investment trust that owns one of the largest portfolios of market-leading gaming, hospitality and entertainment destinations, including the world-renowned Caesars Palace. VICI Properties' national, geographically diverse portfolio consists of 29 gaming facilities comprising over 48 million square feet and features approximately 19,200 hotel rooms and more than 200 restaurants, bars and nightclubs. Its properties are leased to industry leading gaming and hospitality operators, including Caesars Entertainment, Inc., Century Casinos Inc., Hard Rock International, JACK Entertainment and Penn National Gaming, Inc. VICI Properties also owns four championship golf courses and 34 acres of undeveloped land adjacent to the Las Vegas Strip. VICI Properties' strategy is to create the nation's highest quality and most productive experiential real estate portfolio.

Full VICI Calculator →
📬

Get this CNBI vs VICI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CNBI vs SCHDCNBI vs JEPICNBI vs OCNBI vs KOCNBI vs MAINCNBI vs NNNCNBI vs EPRTCNBI vs ADC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.